@article{SHC5516,
author = {Kentaro Suina and Takehito Shukuya},
title = {Evidence for treatment with anti-PD-1 antibody for thymic cancer: how to identify patients most likely to benefit},
journal = {Shanghai Chest},
volume = {3},
number = {0},
year = {2019},
keywords = {},
abstract = {Thymic epithelial tumor (TET) is a rare disease with an annual incidence of 0.15 cases per 100,000 people (1). Accordingly, thymic carcinoma (TC) accounts for approximately 14% of all such cases (2). However, developing treatments for TC is fraught with many practical challenges, whereas critical medical needs remain unmet.},
issn = {2521-3768}, url = {https://shc.amegroups.org/article/view/5516}
}